The first phase I erdafitinib trial enrolled 187 patients with advanced or refractory solid tumors, including 11 CCA patients.5 All 11 patients had FGFR alterations (including 1 FGFR2 and 2 FGFR3 mutations). Here, FGFR2 is linked to cholangiocarcinoma.